Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
E Lestang, P Peterlin, Y Le Bris… - European Journal of …, 2017 - Wiley Online Library
Objective The role of allogenic stem cell transplantation (ASCT) is still debated in
myelofibrosis (MF). Methods A retrospective analyzed was performed to compare the …
myelofibrosis (MF). Methods A retrospective analyzed was performed to compare the …
[HTML][HTML] Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor …
L Masarova, UR Popat, P Bose, RE Champlin… - Blood, 2016 - Elsevier
Introduction: Allogeneic stem cell transplantation (SCT) is a curative option recommended
for patients with Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 …
for patients with Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 …
[HTML][HTML] The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review
M Tiribelli, F Palandri, E Sant'Antonio… - Bone Marrow …, 2020 - nature.com
Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
curative therapy for myelofibrosis (MF). Despite many improvements, outcomes of HSCT are …
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by …
VWK Li, R Yim, P Lee, L Chin, L Au, GMK Leung… - Annals of …, 2023 - Springer
Relapse after allogeneic haematopoietic stem cell transplantation (HSCT) is one of the key
determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this …
determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this …
Allogeneic stem cell transplantation for myelofibrosis in 2012
DP McLornan, AJ Mead, G Jackson… - British journal of …, 2012 - Wiley Online Library
Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …
Allogeneic stem-cell transplantation for myelofibrosis
N Lavi, JM Rowe, T Zuckerman - Current Opinion in Hematology, 2017 - journals.lww.com
HSCT remains a highly relevant treatment option for myelofibrosis in the era of JAK
inhibitors. Recent advances may contribute to a refined definition of HSCT eligibility and …
inhibitors. Recent advances may contribute to a refined definition of HSCT eligibility and …
Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms
R Tamari, H Castro-Malaspina - Current Opinion in Hematology, 2015 - journals.lww.com
Improvements in the field of allo-HSCT, the ability to improve patient's performance status
prior to transplant with JAK1/2 inhibitors and a more accurate disease risk stratification …
prior to transplant with JAK1/2 inhibitors and a more accurate disease risk stratification …
Effect of pre‐transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis
S Cyriac, S Prem, MQ Salas, S Chen… - European Journal of …, 2021 - Wiley Online Library
Allogeneic hematopoeitic cell transplantation (allo‐HCT) is the only curative treatment for
myelofibrosis (MF). We evaluate the impact of various factors on survival outcomes post …
myelofibrosis (MF). We evaluate the impact of various factors on survival outcomes post …
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International …
New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …
leading to increased complexity in the management of patients with myelofibrosis. To inform …
Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation
M Gooptu, HT Kim, K Chen, A Mullally, J Antin, C Cutler… - Blood, 2023 - Elsevier
Introduction: The reported impact of gene mutations, including JAK2-V617F, other MPN
phenotypic drivers and additional cooccurring mutations on outcomes after allogeneic …
phenotypic drivers and additional cooccurring mutations on outcomes after allogeneic …